$SMMT News

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Stifel Maintains Buy on Summit Therapeutics, Lowers Price Target to $38

Guggenheim Maintains Buy on Summit Therapeutics, Lowers Price Target to $38

Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

Summit Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

Summit Therapeutics Plans To Offer $380M Common Shares

Summit Therapeutics Raises Going Concern Doubt, Says Current Cash Is Insufficient To Fund Operations For The Next 12 Months

Summit Therapeutics Q2 Adj. EPS $(0.19) Beats $(0.28) Estimate

HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral

Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data

Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug

Summit Therapeutics Reports Updated Overall Survival Data In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved OS Trend; PDUFA Goal Action Date November 14

Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

Summit Therapeutics Signs Agreement With Biossil For Sale Of Ridinilazole, Investigational Phase III Precision Antibiotic Owned By Summit

Summit Therapeutics finance chief tops list of public CFO pay in 2025

Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet

Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It